{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T04:10:16Z","timestamp":1748578216890,"version":"3.41.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>This study aimed to investigate the impact of baseline nasal polyp score (NPS) on the effectiveness of dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this retrospective observational study, 80 CRSwNP patients treated with dupilumab 300\u00a0mg biweekly at a tertiary referral center were stratified according to the baseline NPS into two groups: low-NPS (&lt;\u20095) and high-NPS (\u2265\u20095). Treatment outcomes were evaluated at the 6-month follow-up visit and compared.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Both groups showed significant clinical improvements. The NPS decreased significantly in both low- and high-NPS groups, from a mean score of 3.2 to 0.8 and from 6.1 to 1.4, respectively (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 for both). SNOT-22 scores improved significantly in both groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 for both), though the reduction was greater in the high-NPS group (35.5 vs. 23.9, <jats:italic>p<\/jats:italic>\u2009=\u20090.018). There were no significant differences between low- and high NPS groups in proportions of NPS reduction of \u2265\u20091 (89% vs. 95%, <jats:italic>p<\/jats:italic>\u2009=\u20090.396) and clinically significant SNOT-22 improvement (=\u2009reduction\u2009&gt;\u200912 or follow-up SNOT\u2009&lt;\u200940; 80% vs. 86%, <jats:italic>p<\/jats:italic>\u2009=\u20090.544).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our results suggests that dupilumab is effective in CRSwNP treatment, regardless of baseline nasal polyp size. Both small and large polyp groups showed significant improvements in NPS and patient-reported outcome measures. Future, prospective studies are warranted to validate these findings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00405-025-09275-2","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T17:47:05Z","timestamp":1740073625000},"page":"3329-3334","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical effectiveness of dupilumab in CRSwNP: unaffected by baseline nasal polyp size in real-world settings"],"prefix":"10.1007","volume":"282","author":[{"given":"Michael","family":"Habenbacher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Moser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Abaira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Holzmeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Pock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Walla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2530-9931","authenticated-orcid":false,"given":"Alexandros","family":"Andrianakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"9275_CR1","doi-asserted-by":"publisher","unstructured":"Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S et al (2020) European position paper on rhinosinusitis and nasal polyps. Rhinology 58(Suppl S 291\u2013464. https:\/\/doi.org\/10.4193\/Rhin20.600","DOI":"10.4193\/Rhin20.600"},{"issue":"6","key":"9275_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2500\/ajra.2013.27.3981","volume":"27","author":"MR Chaaban","year":"2013","unstructured":"Chaaban MR, Walsh EM, Woodworth BA (2013) Epidemiology and Differential diagnosis of nasal polyps. Am J Rhinol Allergy 27(6):473\u2013478. https:\/\/doi.org\/10.2500\/ajra.2013.27.3981","journal-title":"Am J Rhinol Allergy"},{"issue":"10209","key":"9275_CR3","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394(10209):1638\u20131650. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1","journal-title":"Lancet"},{"issue":"10","key":"9275_CR4","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1007\/s00405-024-08725-7","volume":"281","author":"M Reale","year":"2024","unstructured":"Reale M, Licci G, Orlando P, Matucci A, Trabalzini F, Maggiore G, Gallo O (2024) Efficacy and safety of dupilumab in the treatment of CRSwNP in the real-life setting: a review of the literature. Eur Arch Otorhinolaryngol 281(10):5023\u20135031. https:\/\/doi.org\/10.1007\/s00405-024-08725-7","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"3","key":"9275_CR5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4193\/Rhin22.489","volume":"61","author":"WJ Fokkens","year":"2023","unstructured":"Fokkens WJ, Viskens AS, Backer V, Conti D, De Corso E, Gevaert P et al (2023) EPOS\/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with nasal polyps 2023. Rhinology 61(3):194\u2013202. https:\/\/doi.org\/10.4193\/Rhin22.489","journal-title":"Rhinology"},{"key":"9275_CR6","doi-asserted-by":"publisher","first-page":"110316","DOI":"10.1016\/j.jpsychores.2020.110316","volume":"140","author":"D Riedl","year":"2021","unstructured":"Riedl D, Dejaco D, Steinbichler TB, Innerhofer V, Gottfried T, Bektic-Tadic L, Giotakis AI, Rumpold G, Riechelmann H (2021) Assessment of health-related quality-of-life in patients with chronic Rhinosinusitis - Validation of the German sino-nasal outcome Test-22 (German-SNOT-22). J Psychosom Res 140:110316. https:\/\/doi.org\/10.1016\/j.jpsychores.2020.110316","journal-title":"J Psychosom Res"},{"key":"9275_CR7","unstructured":"\u00d6sterreichische Sozialversicherung Infotool zum Erstattungskodex. Available from: https:\/\/www.sozialversicherung.at\/oeko\/views\/index.xhtml. Accessed on 03 December 2024"},{"issue":"10","key":"9275_CR8","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1111\/all.15772","volume":"78","author":"E De Corso","year":"2023","unstructured":"De Corso E, Pasquini E, Trimarchi M, La Mantia I, Pagella F, Ottaviano G et al (2023) Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational phase IV real-life study (DUPIREAL). Allergy 78(10):2669\u20132683. https:\/\/doi.org\/10.1111\/all.15772","journal-title":"Allergy"},{"issue":"4","key":"9275_CR9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.4193\/Rhin23.278","volume":"62","author":"A Kiricsi","year":"2024","unstructured":"Kiricsi A, Bella Z, Kraxner H, Szaloki T, Fent Z, Liktor B et al (2024) Real-life effectiveness of dupilumab in chronic rhinosinusitis with nasal polyps. Results from eight Hungarian centres with 12-month follow-up. Rhinology 62(4):410\u2013420. https:\/\/doi.org\/10.4193\/Rhin23.278","journal-title":"Rhinology"},{"key":"9275_CR10","doi-asserted-by":"publisher","first-page":"322","DOI":"10.4193\/Rhin22.011","volume":"3","author":"SS Jeong","year":"2022","unstructured":"Jeong SS, Chen T, Nguyen SA, Edwards TS, Schlosser RJ (2022) Correlation of polyp grading scales with patient symptom scores and olfaction in chronic rhinosinusitis: a systematic review and meta-analysis. Rhinology 3:322\u2013334. https:\/\/doi.org\/10.4193\/Rhin22.011","journal-title":"Rhinology"},{"issue":"1","key":"9275_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40463-023-00663-4","volume":"52","author":"NJ Campion","year":"2023","unstructured":"Campion NJ, Brugger J, Tu A, Stanek V, Brkic FF, Bartosik TJ, Liu DT, Hoehl BS, Gangl K, Eckl-Dorna J, Schneider S (2023) The real life efficacy of dupilumab is independent of initial polyp size and concomitant steroids in CRSwNP. J Otolaryngol Head Neck Surg 52(1):56. https:\/\/doi.org\/10.1186\/s40463-023-00663-4","journal-title":"J Otolaryngol Head Neck Surg"},{"issue":"5 Suppl","key":"9275_CR12","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.otohns.2006.09.014","volume":"135","author":"BJ Ferguson","year":"2006","unstructured":"Ferguson BJ, Fokkens W, Jenkins SG, Lund VJ, Mafee MF, Naclerio RM et al (2006) Rhinosinusitis Initiative. Rhinosinusitis: developing guidance for clinical trials. Otolaryngol Head Neck Surg 135(5 Suppl):S31\u201380. https:\/\/doi.org\/10.1016\/j.otohns.2006.09.014","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"6","key":"9275_CR13","doi-asserted-by":"publisher","first-page":"552","DOI":"10.4193\/Rhin21.253","volume":"59","author":"KM Phillips","year":"2021","unstructured":"Phillips KM, Houssein FA, Boeckermann LM, Singerman KW, Liu DT, Sedaghat AR (2021) Multi-institutional minimal clinically important difference of the 22-item Sinonasal Outcome Test in medically managed chronic rhinosinusitis. Rhinology 59(6):552\u2013559. https:\/\/doi.org\/10.4193\/Rhin21.253","journal-title":"Rhinology"},{"issue":"1","key":"9275_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","volume":"147","author":"C Bachert","year":"2021","unstructured":"Bachert C, Han JK, Wagenmann M, Hosemann W, Lee SE, Backer V et al (2021) EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol 147(1):29\u201336. https:\/\/doi.org\/10.1016\/j.jaci.2020.11.013","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"9275_CR15","first-page":"203","volume":"61","author":"R Boscke","year":"2023","unstructured":"Boscke R, Heidemann M, Bruchhage KL (2023) Dupilumab for chronic rhinosinusitis with nasal polyps: real-life retrospective 12-month effectiveness data. Rhinology 61(3):203\u2013213","journal-title":"Rhinology"},{"issue":"3","key":"9275_CR16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4193\/Rhin21.401","volume":"60","author":"PG Djupesland","year":"2022","unstructured":"Djupesland PG, Reitsma S, Hopkins C, Sedaghat AR, Peters A, Fokkens WJ (2022) Endoscopic grading systems for nasal polyps: are we comparing apples to oranges? Rhinology 60(3):169\u2013176. https:\/\/doi.org\/10.4193\/Rhin21.401","journal-title":"Rhinology"},{"issue":"6","key":"9275_CR17","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/alr.22936","volume":"12","author":"AK Parasher","year":"2022","unstructured":"Parasher AK, Gliksman M, Segarra D, Lin T, Rudmik L, Quast T (2022) Economic evaluation of Dupilumab Versus endoscopic sinus surgery for the treatment of chronic Rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol 12(6):813\u2013820. https:\/\/doi.org\/10.1002\/alr.22936","journal-title":"Int Forum Allergy Rhinol"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-025-09275-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-025-09275-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-025-09275-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T19:41:23Z","timestamp":1748547683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-025-09275-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["9275"],"URL":"https:\/\/doi.org\/10.1007\/s00405-025-09275-2","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"type":"print","value":"0937-4477"},{"type":"electronic","value":"1434-4726"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"7 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Medical University of Graz (approval code: 1086\/2024). Due to the retrospective nature of this study, requirement of patient\u2019s informed consent was waived by the Institutional Review Board of Medical University of Graz.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}